ARDX
ARDX clinical trials: ARDELYX, INC.
Every trial on ClinicalTrials.gov where ARDELYX, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 32
- Trials linked
- 29
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ARDX on the catalyst calendar · ARDX registry changes
- Primary completion Aug 20, 2026ActualPhase 3NCT05643534Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsArdelyx · Irritable Bowel Syndrome With Constipation (IBS-C)CompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2026ActualPhase 2NCT065535474-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsArdelyx · Irritable Bowel Syndrome With Constipation (IBS-C)CompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2027Sponsor estimatePhase 3NCT07382167A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsArdelyx · Chronic Idiopathic Constipation (CIC)RecruitingARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2031Sponsor estimatePhase 3NCT05905926Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CArdelyx · Irritable Bowel Syndrome With Constipation (IBS-C)Enrolling by invitationARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2024ActualPhase 1NCT06203444An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating FemalesArdelyx · LactationCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2019ActualPhase 3NCT03427125A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisArdelyx · HyperphosphatemiaCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2021ActualPhase 4NCT04549597Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of HyperphosphatemiaArdelyx · Chronic Kidney Disease Requiring Chronic DialysisCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2021ActualPhase 4NCT03988920A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HPArdelyx · HyperphosphatemiaCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2019ActualPhase 2/Phase 3NCT03824587Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyArdelyx · HyperphosphatemiaCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2021ActualPhase 2NCT04780841A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of HyperkalemiaArdelyx · HyperkalemiaCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2017ActualPhase 3NCT02727751A Long-Term Safety Study of Tenapanor for the Treatment of IBS-CArdelyx · Constipation Predominant Irritable Bowel SyndromeCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 2NCT02081534Dose Finding Study to Treat High Phosphate Levels in the Blood.Ardelyx · HyperphosphatemiaCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 3NCT02675998An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)Ardelyx · HyperphosphatemiaCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2013ActualPhase 2NCT01764854Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on HemodialysisArdelyx · End Stage Renal DiseaseCompletedARDXLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2015ActualPhase 2NCT01847092A Study in CKD Patients With Type 2 Diabetes Mellitus and AlbuminuriaArdelyx · Chronic Kidney DiseaseCompletedARDXLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2017ActualPhase 3NCT02686138A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-CArdelyx · Constipation Predominant Irritable Bowel SyndromeCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2017ActualPhase 3NCT02621892A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-CArdelyx · Constipation Predominant Irritable Bowel SyndromeCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2014ActualPhase 2/Phase 3NCT01923428The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)Ardelyx · Constipation Predominant Irritable Bowel SyndromeCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2017ActualPhase 2NCT03018067A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of HyperkalemiaArdelyx · HyperkalemiaTerminatedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2011ActualPhase 2NCT01340053A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)Ardelyx · Constipation Predominant Irritable Bowel SyndromeCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2011ActualPhase 1NCT02819687Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy VolunteersArdelyx · HealthyCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT02796131Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy VolunteersArdelyx · HealthyCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2013ActualPhase 1NCT02226783D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy SubjectsArdelyx · Healthy Volunteers Food Interaction StudyCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 1NCT02140281To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy VolunteersArdelyx · Healthy VolunteersCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 1NCT02140268To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy VolunteersArdelyx · Healthy VolunteersCompletedARDXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 7 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner